Identification and Validation of Putative Nesprin Variants by Autore, Flavia et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Autore, F., Shanahan, C. M., & Zhang, Q. (2016). Identification and Validation of Putative Nesprin Variants. In
Methods in Molecular Biology . (Vol. 1411, pp. 211-220). Springer.
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
 1
 
Identification and validation of putative nesprin variants 
 
Flavia Autore1, 2, Catherine M. Shanahan2, Qiuping Zhang2 
 
 
1Randall Division of Cell and Molecular Biophysics, King’s College London, UK 
 
2British Heart Foundation Centre of Research Excellence, Cardiovascular Division, 
King’s College London, UK 
 
+Corresponding author: Dr. Qiuping Zhang 
King’s College London,  
Cardiovascular Division, 
James Black Centre, 
125 Coldharbour Lane, 
London SE5 9NU 
 UK 
 
Tel: +44 20 78485222 
Fax: +44 20 78485193 
Email: qp.zhang@kcl.ac.uk 
 
 
 
Running Head:  Challenges of studying nesprins 
 
 2
 
 
Summary 
Nesprins are a family of multi-isomeric scaffolding proteins that were originally 
identified at the nuclear envelope (NE), where they bind to lamin A/C, emerin and 
SUN-domain containing proteins, to form the LInker of Nucleoskeleton-and-
Cytoskeleton (LINC) complex that connects the NE to the actin cytoskeleton. However, 
nesprin genes also give rise to a variety of tissue specific variants of different sizes with 
potential roles beyond the NE. These variants are generated through alternative 
initiation, termination and splicing, which makes nesprin biology very complex to study 
due to the difficulty in generating specific antibodies and/or short interfering RNAs 
(siRNA) to particular isoforms. In order to distinguish genuine nesprin variants and 
eliminate confusion with degradation products of larger nesprin isoforms, in this 
chapter we discuss methods  including 5’ and 3’ Rapid Amplification of cDNA Ends 
(RACE) and RT-PCR in combination with EST database searching, for identifying and 
validating putative nesprin isoforms. This information is essential to allow a better 
understanding of nesprin functions in different cell types. 
 
Key words: Nesprins, Alternative Splicing, EST database, RACE, Multi-Tissue RT-
PCR. 
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1. Introduction 
Nesprins comprise a family of multi-isomeric scaffolding proteins that were originally 
identified as components of the nuclear envelope (NE) [1]. There are four mammalian 
genes (SYNE 1-4) encoding nesprin proteins.  Nesprin-1, -2 and -3 are ubiquitously 
expressed in human tissues, while nesprin-4 is mainly expressed in highly polarized 
epithelial cells [2-5]. All four nesprin proteins contain a C-terminal Klarsicht/ANC-
1/Syne Homology (KASH) domain, which mediates the interaction with SUN domain 
containing proteins (SUN1 and SUN2) at the nuclear membrane, forming the LInker of 
the Nucleoskeleton and the Cytoskeleton (LINC) complex [2-4]. The nesprins reside in 
the outer nuclear membrane (ONM) where they interact with cytoskeletal filaments. 
SUN 1/2 reside at the inner nuclear membrane (INM) and bind to lamin A/C directly 
via their nucleoplasmic domain. Therefore the LINC complex provides a physical 
connection between the nucleus and the cytoskeleton [5,6]. Nesprins-1 and -2 are also 
able to bind to lamin A/C and emerin at the INM [1,7]. Mutations in the genes encoding 
all of these proteins contribute to Emery–Dreifuss muscular dystrophy (EDMD) and 
dilated cardiomyopathy (DCM)[8,9], indicating that nuclear-cystoskeletal connection 
is fundamental to muscle cell function.  
 
There are sequence diversities at the N-terminus of nesprins, allowing them to bind to 
different components of the cytoskeleton: actin filaments, microtubules (MT) and 
intermediate filaments (IF).  Nesprin-1 and nesprin-2 are defined as giant proteins due 
to their molecular weights of ~1 MDa and ~800 kDa respectively. Both are comprised 
of N-terminal paired Calponin Homology domains (CHD) that bind to F-actin, a C-
terminal KASH domain, and a central Spectrin Repeat (SR)-containing rod domain, 
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mediating protein-protein interactions [10,11]. Nesprin-3 and nesprin-4 are 
characterised by a much less extended rod domain, which reflects their lower molecular 
weights of 110 and 42 kDa respectively [11]. Despite lacking the CHDs, they are both 
able to bind cytoskeleton filaments: nesprin-3 binds IFs through a plectin-binding 
domain, whereas nesprin-4 interacts with kinesin-1, a motor protein associated with 
MT networks [12,13].  
 
Nesprin-1 and -2 are encoded by 146 and 115 exons respectively, which give rise to a 
large number of different variants[14]. Most variants have overlapping domains, 
indicating that the expression of nesprin variants is a highly flexible and regulated 
process. This flexibility is likely an adaptive response that cells require to meet the 
requirements of different cellular cues or stimuli. In particular in muscle tissue, nesprins 
not only switch isoform expression of the same gene, but also change expression 
between the different nesprin genes.  For example, during human muscle development, 
expression level of nesprin-1 giant increases during early myogenesis in vitro, while 
nesprin-2 partially replaces nesprin-1 at the NE. Ultimately, the shorter nesprin KASH 
isoforms become the dominant variants during the transition from immature to mature 
muscle fibres in vivo [15].  
 
We documented that nesprin-1 and -2 give rise to a vast array of tissue specific isoforms 
of different sizes [14] including i) isoforms lacking the KASH domain  (14 for nesprin-
1 and 5 for nesprin-2); ii) isoforms lacking the CHDs (16 for nesprin-1 and 12 for 
nesprin-2) [16], and iii) SR-only isoforms for nesprin-1 [17]. The isoform repertoire 
reflects emerging new functions of nesprins beyond the NE. The isoforms are generated 
by alternate promotor usage, pre-mRNA 3’ end processing, and alternative splicing 
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(including or excluding cassette exons) [14,16,18]. For example, nesprin-2α1 and -2α2 
variants are generated via different initiation within 5’ untranslated region (UTR) 
(Figure 1A) [1,7].  Alternative splicing is another mechanism by which exons are 
removed from the mature nesprin mRNA. For example, nesprin-1∆KASH is generated 
through the removal of cassette exon 145 of nesprin-1 resulting in a stop codon at exon 
146 and deletion of the KASH domain (Figure 1B). Similarly, nesprin-2∆KASH1 is 
generated through the removal of exons 111–112 (Figure 1C).   In contrast, nesprin-
2∆KASH2 is generated via different termination point through utilisation of an 
alternative 3’UTR juxtaposed to exon 115 via a retained intron, to produce an 
alternative variant (Figure 1D). These alternative transcript generation mechanisms 
have also been observed experimentally in other studies of nesprin-1 variants [19]. 
All the nesprin isoforms published so far were predicted mainly using the NCBI EST 
(database for “Expressed Sequence Tag”) [20], but only a small subset has been verified 
experimentally. The variety of sizes and isoforms that can be generated make nesprin 
biology very complex due to the difficulty in generating (1) specific antibodies and (2) 
short interfering RNAs (siRNA) [21]: 
(1) The use of specific antibodies is limited to a small subset of isoforms, because the 
antibodies available detect not only the real products of alternative splicing (of which 
there may be many), but often degradation products that are commonly present during 
the manipulation of proteins of large molecular weight [14,15,22].  (2) In addition, the 
most common event for alternate isoform formation is the use of alternative 5’ and 3’ 
UTRs, with common coding exons which complicates the exclusive knockdown of a 
particular isoform as it is likely to interfere with the expression of other variants. In the 
literature the siRNAs currently used for knocking down small isoforms also hamper the 
expression of the giant nesprins due to this lack of specifically targeted exon 
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regions[14]. Moreover, the efficiency of knockdown can only be detected at the RNA 
level by qPCR using oligonucleotides designed specifically for each of the siRNA 
targeted exons, because the protein expression level is usually not verifiable due to lack 
of antibody specificity as described above in (1)[14]. 
 
We have employed multiple techniques to identify and verify transcripts encoding 
novel nesprin variants.  In some cases, these analyses have enabled us to identify 
variants that do have some sequence specificity at the protein level which enables the 
generation of more selective antibody tools. Therefore the identification and 
verification of novel transcripts is essential for a complete understanding of nesprin 
biology [1,14,7]. In this chapter we discuss the techniques we have used including: i) 
5’ and 3’ Rapid Amplification of cDNA Ends (RACE) for identifying cDNA ends that 
represent novel 5’ and/or 3’ UTRs, in combination with the EST database analysis, in 
which there is a vast collection of partial sequences of cDNA clones available; ii) RT-
PCR from multi-tissue cDNAs using alternatively combined 5’ and 3’ UTRs for 
identifying and validating putative isoforms [1,16,7,23].  
 
2. MATERIALS: 
A range of gene-specific primers for amplification of the region of interest of the cDNA 
(see Note 1 and Figure 2) 
Marathon-Ready cDNA from a tissue of interest (Clontech) 
Advantage 2 PCR kit (Clontech) 
GC-RICH PCR system (Roche Applied Science) 
First Strand cDNA (OriGene) 
DreamTag Green PCR master mix (Fisher Scientific) 
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pGEM-T Easy vector (Promega) 
Rotor-Gene RG 3000 (Corbett Research) 
 
3. METHODS 
3.1 Bioinformatics analyses 
Published nesprin-1 and nesprin-2 UTRs were identified via screening the NCBI 
expressed sequence tag (EST) database (http://www.ncbi.nlm.nih.gov/dbEST/) [20], 
which contains partial sequences of cDNA clones ranging from ~200 to ~ 700 bp.  To 
screen for novel nesprin UTRs in the EST database: 
1. Submit consecutive nesprin cDNA sequences of 1 kb with 500 bp overlapping, 
covering the entire gene length, to the EST database [14].  
2. Select the 5’UTRs containing an identifiable and viable Kozak sequence near 
the first start codon for verification.  
3. Filter the detected 3’ UTRs with polyadq software 
(http://rulai.cshl.org/tools/polyadq/polyadq_form.html) [24] (see Note 1). 
 
3.2 Rapid Amplification of cDNA Ends (RACE) 
RACE is a suitable method to obtain  full-length novel isoforms, and only requires 
knowledge of a small internal region of the cDNA sequence as well as both an adaptor-
specific primer and a gene specific primer (GSP) [25]. The presence of a known specific 
adaptor sequence at the 5’ or 3’ end of the cDNA is essential for the libraries being used 
in RACE.  Furthermore, a second PCR reaction (named nested PCR) is often required, 
by using the PCR product from the initial run to produce a more specific amplification 
product. GSP (including nested GSP) design is an important step to obtain efficient and 
specific PCR amplifications (see Note 2). 
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1. Design GSP Primers for 5’ or 3’ RACE against the region of interest on the 
gene, as illustrated in Figure 2 and in the Marathon-ready cDNA user manual 
(Clontech). 
2. Perform an initial round of PCR reactions using Advantage 2 polymerase and 
the Marathon-Ready cDNA (Clontech) according to manufacturer’s protocol, 
also briefly described in Table 1, using PCR cycling parameters as follows: 
94ºC for 1 min 
30 cycles: 
• 94ºC 30 sec (denaturation) 
• 68ºC 4 min (anneal/extension ) 
70ºC for 10 min (final extension) 
3. Dilute the initial PCR product (1:50) with PCR grade water, and use 5µl from 
the dilution for nested PCR reactions with a nested adapter primer and a nested 
GSP (NGSP) (see Note 3).Use PCR cycling parameters as follows: 
94ºC for 1 min 
20 cycles: 
• 94ºC 30 sec  
• 68ºC 4 min 
70ºC 10 min 
4. Run the nested PCR products on an agarose gel, excise the desired fragments 
from the gel and clone into pGEM-T Easy vector (Promega). 
5.  Subject each cloned fragment to sequencing. Align the obtained sequences 
against the appropriate NCBI species genome to identify novel cDNA ends, 
which will be either upstream or downstream of the cDNA region of interest. 
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3.3 Multi-tissue  RT-PCR 
To characterise the RACE PCR products and validate expression of the putative 
isoform at RNA level, RT-PCR is required. To amplify short transcripts, design the 5’ 
and 3’ GSPs to either existing or newly identified regions of 5’ and 3’ UTRs identified 
from the EST database analysis and/or RACE above. For larger transcripts, design a 5’ 
GSP or 3’ GSP to the newly identified regions of 5’UTR or 3’UTR, and a 3’ GSP or 5’ 
GSP against the nearest coding exon, or primers in a range of exons (see Note 4) [14]. 
1. Perform RT-PCR  on a multiple tissue cDNA panel (Origene) using GC-RICH 
PCR system (Roche Applied Science) according to manufacturer’s protocol 
(Table 2 and 3), also amplifying housekeeping genes as controls. Use PCR 
cycling  parameters as follows: 
95ºC for 3 min 
30-40 cycles: 
• 95ºC 30 sec  
• 48-55℃ 1 min (depending on the required annealing temperature for 
different primers) 
• 68ºC 1-3 min (depending on the length of putative isoforms) 
68ºC for 7 min 
 
2. Analyse the PCR products by agarose gel electrophoresis. Excise and clone the 
PCR product into a pGEM-T Easy vector (Promega). Subject clones to DNA 
sequencing for further validation. 
 
3.4 Alternative Splicing of Cassette Exons 
Putative cassette exons of nesprins can be identified using EST databases. The resulting 
alternative splicing events could either occur in multiple variants or be specific for a 
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single variant, which are also likely to be activated in a tissue specific manner [14]. 
These post-transcriptional events would further increase the complexity of nesprin 
variants [18]. 
1. To verify the occurrence of alternative splicing events, design specific 
primers that target the exons located on either side of the identified cassette 
exons via the EST database analysis 
2.  Use the designed primers to perform PCR screening of cDNA libraries from 
different tissues of interest (see Note 5) [14]. 
3. Perform all PCR reactions as described in section 3.3 using GC-RICH PCR 
system, or as in Table 4, using the following PCR cycling parameters: 
95ºC 1 min 
30 cycles: 
• 95ºC 30 sec  
• 55ºC 1 min (depending on the required annealing 
temperature for different primers) 
• 72ºC 1 min per kb  
72ºC 10 min 
3. Purify and clone the PCR products, then subject to DNA sequence for 
validation, as described in section 3.3 (see Note 6). 
 
4. Notes 
1. General rules for designing primers are applied. Efficient RACE primers 
must be specific for their target sequences in order to form stable duplexes 
without forming secondary structures such as hairpin loops, as it may 
interfere with polymerisation. For advice on RACE Primer design, refer to 
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the Marathon-ready cDNA user manual (Clontech). Adaptors required for 
RACE are ligated and ready for use in the Marathon-Ready cDNA kit. 
2. Only the 3’UTRs containing a poly (A) tail or at least one poly (A) site 
downstream of the initial open reading frame (ORF) termination are 
selected for further experiments. 
3. A nested PCR reaction is performed using the PCR product from the initial 
run for a more specific amplification product. For nested RACE, the nested 
GSP (NGSP) is designed to anneal with 1-10 nucleotides downstream of the 
GSP used in the first round of amplification (for 5’ RACE) or upstream of 
the GSP (for 3’ RACE). 
4. For validation of 5’UTRs, the forward primer is designed within the 5’UTR 
and the reverse primer within the second coding exon to control for genomic 
contamination. For validation of 3’UTRs, the forward primer is designed 
within the second to last coding exon and the reverse primer within the 
3’UTR to also control for genomic contamination.  
5. For cassette exons (either included and excluded), forward and reverse 
primers should be separated by at least one exon-intron boundary to control 
for genomic contamination.  
6. There are some examples for cassettes exons described for nesprins. When 
PCR amplification was carried out across nesprin-1 exon 93 (one of the 
cassettes detected via EST database searching), two PCR products were 
obtained from two different cDNA libraries. One PCR product showed the 
presence of the exon 93 while the other showed absence of the exon, which 
encodes a unique 47 amino acid peptide sequence. Nesprin-2 also showed 
its propensity of tissue-specific alternative splicing. For example, regarding 
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exon 107, another cassette detected by EST, two PCR products were 
detected in U2OS cells, either containing or missing exon 107, which 
encodes a unique 23 amino acids. Only isoforms containing exon 107 were 
expressed in vascular smooth muscle cells [14]. 
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Table 1: RACE PCR Recipe (50 µl): 
RACE ready cDNA 5 µl 
10X Advantage 2 PCR Buffer 5 µl 
dNTP mix (10 mM) 1 µl 
Adaptor primer (10 µM) 1 µl 
GS primer (10 µM) 1 µl 
Advantage 2 Polymerase 1 µl 
Nuclease-free water to 50 µl 
 
Table 2: GC-Rich PCR Master Mix 1 (35 µl): 
First strand cDNA 50 ng 
dNTP mix (10 mM) 2 µl 
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Forward primer (5 µM) 2 µl 
reverse primer (5 µM) 2 µl 
5M GC Rich Resolution 5 µl 
PCR grade water to 35 µl 
 
Table 3: GC-RICH PCR Master Mix 2 (15µl):  
PCR grade water 4 µl 
5x GC Rich PCR Buffer 10 µl 
GC Rich Enzyme  mix  1 µl 
 
Table 4: RT-PCR recipe (50 µl): 
cDNA 50 ng 
2x Taq master mix* 25 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
Nuclease-free water to 50 µl 
* DreamTag Green PCR master mix contains Taq polymerase, dNTP 
and reaction buffer at 2x concentration.   
Figure 1. Generation of nesprin-2α1 & 2α2, as well as nesprin-1 and -2 ∆KASH variants. Nesprin-2α1 and -2α2 variants were generated
via the potential combinations of 5’ and 3’UTRs (A). Nesprin-1∆KASH and nesprin-2∆KASH1 were generated through the removal of
cassette exon 145 (B) and exons 111–112 (C) respectively via the indicated splicing events (splicing shown in dash lines). Nesprin-2
∆KASH2 was generated through utilisation of an alternative 3’ UTR juxtaposed to exon 115 (D).
*
3’UTR
Intron
Exon
5’UTR
Transcription start
Stop codon
C. Nesprin-2∆KASH1
D. Nesprin-2∆KASH2
B. Nesprin-1∆KASH
110 113 116
110 113 116
2α22α1
110 113 116
A. Nesprin-2α1 & 2α2
143 144 145 146
*
Figure 2. Illustration of the template and primers used in Marathon RACE reactions. AP1 and AP2: adaptor primers
1 and 2; GSP and NGSP: gene specific primers, GSP1 & NGSP1 for 5’RACE, GSP2 & NGSP2 for 3’RACE.
Adaptor –ligated dsDNA template Adaptor Adaptor 
Region of interest 
Region to be 
amplified by 5’RACE 
Region to be 
amplified by 3’RACE 
GSP1NGSP1
NGSP2GSP2
AP1
AP2
AP1
AP2
